Driehaus Capital Management’s Castle Biosciences CSTL Stock Holding History

Driehaus Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-358,200	Closed	-$23.8M	–	385
2021 Q3	$23.8M	Sell	358,200 -21,293	-6%	-$1.5M	0.28%	106
2021 Q2	$27.8M	Buy	379,493 +581	+0.2%	+$38.4K	0.37%	80
2021 Q1	$25.9M	Sell	378,912 -51,844	-12%	-$3.9M	0.38%	77
2020 Q4	$28.9M	Sell	430,756 -12,730	-3%	-$690K	0.47%	64
2020 Q3	$22.8M	Sell	443,486 -5,314	-1%	-$236K	0.47%	59
2020 Q2	$16.9M	Buy	448,800 +41,983	+10%	+$1.43M	0.41%	72
2020 Q1	$12.1M	Buy	406,817 +41,185	+11%	+$1.24M	0.41%	69
2019 Q4	$12.6M	Buy	365,632 +85,231	+30%	+$2.08M	0.33%	86
2019 Q3	$5.07M	Buy	+280,401	New	+$6.22M	0.17%	151

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Driehaus Capital Management's CSTL Position: Q4 2021 in Review

Driehaus Capital Management sold out of Castle Biosciences (CSTL) in Q4 2021, closing a stake of 358,200 shares — an estimated $23.8M sold.

Driehaus Capital Management first reported a position in CSTL in Q3 2019 and held it in 9 quarters. The position peaked at $28.9M in Q4 2020. 159 funds tracked by Wall St. Rank hold CSTL as of Q4 2021.

Driehaus Capital Management reported no remaining Castle Biosciences position as of Q4 2021 after selling out during the quarter.
Driehaus Capital Management sold 358,200 Castle Biosciences shares in Q4 2021, an estimated $23.8M.
Driehaus Capital Management first reported a position in Castle Biosciences in Q3 2019 and held it in 9 quarters.
Driehaus Capital Management's Castle Biosciences position peaked at $28.9M in Q4 2020.
159 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2021.

Based on Driehaus Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.